Latest Commercialisation News

Nimy Resources has successfully raised $1.72 million through an oversubscribed share placement to fast-track copper and gallium exploration at its Mons Project in Western Australia.

Proteomics International Laboratories reported a 26% increase in losses for FY2025, driven by higher operational costs as it advances its Promarker® diagnostic pipeline. Despite an 8% rise in revenue from ordinary activities, total income slipped 2%, underscoring ongoing commercialisation challenges.

Ashley Services Group reported a 60% jump in net profit for FY25 despite a 7.3% revenue decline, focusing on debt reduction and operational efficiency to fuel future growth.

Terragen Holdings reported a $3.72 million loss for FY25, impacted by drought and lower revenues, while launching dry probiotic products targeting feedlots and completing a $4.76 million equity raise.

Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

Hazer Group Limited reported a 124% surge in revenues to $8.5 million for FY25, driven by government grants, while cutting its net loss by 60%. The company advanced its proprietary methane pyrolysis technology, secured a strategic alliance with KBR, and made progress on key projects in Canada and Japan.

Starpharma reports a significant 183% jump in FY25 revenue to $4.9 million, alongside a 31% reduction in losses and a solid cash position of $15.4 million. The biotech firm’s progress underscores growing momentum in its dendrimer technology pipeline.

Victory Metals secures $11.5 million through a strategic placement to accelerate drilling and development at its North Stanmore heavy rare earth project, reinforcing its position as Australia’s leading rare earths explorer.

Calix Limited reported a 17% rise in product and services revenue for FY25, driven by its Magnesia and Leilac businesses, alongside a 23% reduction in operating expenses. The company extended its cash runway to 18 months, supported by a $21 million equity raise, while progressing key decarbonisation projects.

Rhythm Biosciences has completed critical validation of its ColoSTAT colorectal cancer assay and submitted it for ISO15189 accreditation, paving the way for commercialisation. The test demonstrated strong clinical performance, highlighting its potential as a non-invasive diagnostic tool.

Centrepoint Alliance has reported a robust FY25 with 13% revenue growth and a 30% increase in profit before tax, driven by organic adviser expansion, strategic acquisitions, and pioneering technology investments including AI and cybersecurity.